Possible Interaction Between Drugs for COVID19 And Cancer Therapy

At the end of 2019, a new disease was reported in Wuhan China and described such as severe acute respiratory syndrome (SARS). This new virus named SARSCoV-2 S is characterized by high infectivity among humans. Such disease can have no symptoms in some individuals, while in others can provoke flu like symptoms or acute respiratory distress syndrome, pneumonia, and death. At the end of January 2020, the World Health Organization and Public Health Emergency of International Concern declared a pandemic status. Many studies showed a high mortality rate in cancer patient infected by SARS-CoV-2 infection. In this context, the decision of a safe and effective treatment against COVID19 plays a crucial role crucial in these patients Therefore, important questions arose: Can the COVID19 therapies protect everyone and above all cancer patients? and which drug interactions can occur between cancer therapy and COVID19 treatment? In this regard, Covid-19 is a new disease and for this reason it will be necessary to modify constantly pharmacological treatment. In this scenario, the potential drug–drug interactions (DDI) in the cancer patients should be considered to evaluate the risks and benefits of drug combinations.